Dr. Kevin Krenitsky, President of Enzo Clinical Labs, to Present At 27th Annual Lab Institute
NEW YORK--(BUSINESS WIRE)-- Enzo Biochem, Inc. (NYSE:ENZ) announced today that Kevin Krenitsky, MD, President of Enzo Clinical Labs, will present at the 27th Annual Lab Institute '09, sponsored by Washington G2 Reports, on September 23, 2009 in Arlington, Virginia.
Dr. Krenitsky will present at a panel discussion entitled "Going Inside the Boardroom: What's the Bottom Line for Labs During a Time of Economic, Policy and Market Flux?"
Among the meeting's keynote speakers will be the Hon. Newt Gingrich, former Speaker of the U.S. House of Representatives, and Rep. Pete Stark (D-CA), Chairman, House Ways and Means Health Subcommittee.
"The focus of this key conference, which comes at a pivotal time in the debate over health care reform, will be on the impact various proposals will have on diagnostic testing, which, given all the advances being made in diagnosing diseases and how treatments are gauged, will figure importantly in the way medicine is practiced and patients treated in the future," said Dr. Krenitsky. "It is a welcome opportunity that a leading independent laboratory such as Enzo Clinical Labs has been invited to be part of this dialogue."
Inaugurated in 1983, Lab Institute has been the foremost independent national forum for in-depth, balanced presentations and informed viewpoints and insights on major policy and business issues affecting the delivery of quality diagnostic testing and related medical services. It is a unique platform for networking among laboratory, pathology, and hospital/health system constituencies nationwide, and is the only forum on diagnostics where industry, government, and technology come together.
About Enzo
Enzo Biochem is engaged in the research, development, manufacture and licensing of innovative health care products and technologies based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. Enzo's Life Sciences division develops, produces and markets proprietary labeling and detection products for gene sequencing, genetic analysis and immunological research among others. Its catalog of over 30,000 products serves the molecular biology, drug discovery and pathology research markets. The Company's therapeutic division is in various stages of clinical evaluation of its proprietary immune regulation medicines for uveitis and Crohn's disease and conducts pre-clinical research on several candidate compounds aimed at producing new mineral and organic bone, including technology that could provide therapy for osteoporosis and fractures, among other applications. Enzo's Clinical Labs division provides routine and esoteric reference laboratory services for physicians in the New York Metropolitan and New Jersey areas. Underpinning the Company's technology and operations is an extensive intellectual property estate in which Enzo owns or licenses over 240 patents worldwide, and has pending applications for over 200 more. For more information visit our website www.enzo.com.
Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.
Source: Enzo Biochem, Inc.
Released September 18, 2009